Allergy Therapeutics PLC Appointment of new Group auditors (6618V)
April 16 2021 - 1:00AM
UK Regulatory
TIDMAGY
RNS Number : 6618V
Allergy Therapeutics PLC
16 April 2021
Allergy Therapeutics plc
("Allergy Therapeutics", "ATL" or the "Group")
Appointment of new Group auditors
16 April 2021 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
immunotherapy, today announces, that following a competitive tender
process, BDO LLP ("BDO") has been appointed as its external auditor
for the year ended 30 June 2021. The appointment of BDO as auditor
for the following financial year will be subject to approval by
shareholders at the next Annual General Meeting of the Company.
Grant Thornton UK LLP ("Grant Thornton") has now resigned and
has confirmed to the Company that there are no matters which should
be brought to the attention of the creditors or shareholders of the
Group.
The Company would like to thank Grant Thornton for its service
over the past 13 years.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development includes vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Adjuvant systems to boost performance of vaccines outside allergy
are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved over 9% compound annual
growth since formation, employs c.600 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPSFUFUIEFSEIL
(END) Dow Jones Newswires
April 16, 2021 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024